RESUMO
AIM: The purpose of the Imadje study was to confirm the efficacy and safety of imatinib, following resection of kit-positive gastrointestinal stromal tumour (GIST), in the adjuvant setting in the Greek population. PATIENTS AND METHODS: A total of 34 adult patients already receiving imatinib were enrolled. Recurrence-free (RFS) and overall survival, as well as time to treatment failure and safety were assessed. RESULTS: Overall survival could not be estimated in the present study, as no death occurred. Overall, 91.2% of patients were recurrence-free at 36 months, while the median time to treatment failure was 35 months. No new or unexpected safety findings were observed. Mutation analysis in 14 patients showed that the most frequent mutations were located in KIT exon 11 (64.3%) and exon 9 (28.6%). Univariate analysis showed that only surgical resection with a margin classification of R0 was associated with better RFS. CONCLUSION: Adjuvant treatment with imatinib for 3 years in patients with intermediate to high risk of recurrence was proven to prolong RFS, while being well-tolerated and not exhibiting a negative impact on patient compliance with therapy.
Assuntos
Tumores do Estroma Gastrointestinal/tratamento farmacológico , Mesilato de Imatinib/uso terapêutico , Recidiva Local de Neoplasia/patologia , Análise Mutacional de DNA , Intervalo Livre de Doença , Feminino , Grécia , Humanos , Mesilato de Imatinib/efeitos adversos , Estimativa de Kaplan-Meier , Masculino , Pessoa de Meia-Idade , Resultado do TratamentoRESUMO
Chromium-51 (5¹Cr)-ethylene diamino tetraacetic acid plasma clearance is commonly used in glomerular filtration rate measurements. In the presence of additional radionuclides in plasma samples, glomerular filtration rate may be seriously underestimated and a correction of the crosstalk interference may be necessary. This type of correction is problematic in the case of gallium-67 (67Ga) mainly because of the close vicinity of its 300 keV photopeak with that of the 320 keV photopeak of 5¹Cr. A novel method of calculating and removing the interfering 67Ga counts within the 5¹Cr counting window, based on the different decay rates of the two radionuclides, is presented, requiring two series of sample counting in the 5¹Cr counting window only, separated by a 3-day interval. This method was developed to solve a clinical problem and then it was validated by a controlled 67Ga contamination of plasma samples with known counts from 5¹Cr-ethylene diamino tetraacetic acid.
Assuntos
Artefatos , Citratos , Ácido Edético , Gálio , Taxa de Filtração Glomerular , Contagem de Cintilação/métodos , Adulto , Criança , Radioisótopos de Cromo/sangue , Citratos/sangue , Contaminação de Medicamentos , Feminino , Gálio/sangue , Humanos , Reprodutibilidade dos TestesRESUMO
The live birth of a triploidy infant is a very rare event and death usually occurs within the first hours of life. Triploid cases with a survival of more than two months are infrequent. We report on an infant with a 69,XXX chromosome constitution who survived 164 days. Chromosomal analysis demonstrated a 69,XXX karyotype with no evidence of mosaicism. This is the longest survival reported for this condition to date in Greece and the fourth longest worldwide. The infant was admitted to our clinic several times due to respiratory problems, and supplementary oxygen was required. The improved survival of our case was possibly due to better management of respiratory illness and prematurity, and these are essential factors that physicians should consider carefully with such rare cases.